文献速递冠心病

重新审视急性冠脉综合征后12个月双联抗血小板治疗的当代角色

Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary Syndrome.
PubMed 文献 · Circulation · 2024-07-22

该综述指出,尽管欧美指南将ACS后12个月DAPT作为唯一I类推荐,但其证据基础存在误读:CURE试验比较的是DAPT与无DAPT而非最佳疗程,平均DAPT仅9个月;后续试验中替格瑞洛和普拉格雷的中位DAPT分别为9或15个月。出血风险而非缺血风险已成为DAPT疗程的主要调整因素,多种降阶策略可减少出血而不增加缺血风险,12个月DAPT亟需更新。

要点

  • 12个月DAPT的I类推荐缺乏前瞻性验证,源于对CURE等试验的误读。
  • 高出血风险患者应缩短DAPT,高缺血且可耐受者或可延长。
  • 降阶策略(换药、减量、缩短DAPT+替格瑞洛单药)可减少出血不增缺血。

核心结论

  • 12个月DAPT作为ACS后唯一I类推荐缺乏前瞻性证据,导致许多患者过度治疗。
  • 出血风险应作为DAPT疗程调整的主要依据,而非仅缺血风险。

研究设计与样本

  • 综述性文章,基于现有临床试验证据分析ACS后DAPT疗程。

主要发现

  • CURE试验设计为DAPT与无DAPT比较,平均DAPT时长9个月而非12个月。
  • 后续ACS试验非为评估DAPT时长设计,替格瑞洛和普拉格雷的中位DAPT分别为9或15个月。
  • 高出血风险患者延长治疗出血过多且无明确获益。
  • 多种降阶策略较12个月DAPT减少出血而不增加致命或非致命心脑血管缺血风险。

关键数值与推荐

  • 欧美指南将ACS后12个月DAPT列为唯一I类推荐。
  • 高出血风险患者建议DAPT短于12个月,高缺血风险且可安全耐受者建议长于12个月。

临床怎么用

  • 临床应基于出血风险而非仅缺血风险个体化调整DAPT时长。
  • 对高出血风险患者考虑缩短DAPT或采用降阶策略。
  • 对高缺血风险且可耐受者考虑延长DAPT超过12个月。

局限性

  • 缺乏前瞻性验证12个月DAPT疗程的随机对照证据。
  • 现有试验非为评估DAPT时长设计,证据间接。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

For almost two decades, 12-month dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS) has been the only class I recommendation on DAPT in American and European guidelines, which has resulted in 12-month durations of DAPT therapy being the most frequently implemented in ACS patients undergoing percutaneous coronary intervention (PCI) across the globe. Twelve-month DAPT was initially grounded in the results of the CURE (Clopidogrel in Unstable Angina to Prevent Recurrent Events) trial, which, by design, studied DAPT versus no DAPT rather than the optimal DAPT duration. The average DAPT duration in this study was 9 months, not 12 months. Subsequent ACS studies, which were not designed to assess DAPT duration, rather its composition (aspirin with prasugrel or ticagrelor compared with clopidogrel) were further interpreted as supportive evidence for 12-month DAPT duration. In these studies, the median DAPT duration was 9 or 15 months for ticagrelor and prasugrel, respectively. Several subsequent studies questioned the 12-month regimen and suggested that DAPT duration should either be fewer than 12 months in patients at high bleeding risk or more than 12 months in patients at high ischemic risk who can safely tolerate the treatment. Bleeding, rather than ischemic risk assessment, has emerged as a treatment modifier for maximizing the net clinical benefit of DAPT, due to excessive bleeding and no clear benefit of prolonged treatment regimens in high bleeding risk patients. Multiple DAPT de-escalation treatment strategies, including switching from prasugrel or ticagrelor to clopidogrel, reducing the dose of prasugrel or ticagrelor, and shortening DAPT duration while maintaining monotherapy with ticagrelor, have been consistently shown to reduce bleeding without increasing fatal or nonfatal cardiovascular or cerebral ischemic risks compared with 12-month DAPT. However, 12-month DAPT remains the only class-I DAPT recommendation for patients with ACS despite the lack of prospectively established evidence, leading to unnecessary and potentially harmful overtreatment in many patients. It is time for clinical practice and guideline recommendations to be updated to reflect the totality of the evidence regarding the optimal DAPT duration in ACS.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Valgimigli, Landi, Angiolillo, et al. Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary Syndrome. Circulation. 2024. PMID: 39038086. doi:10.1161/CIRCULATIONAHA.124.069012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。